Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD
The FDA has approved extending the dosing intervals for Regeneron’s Eylea HD up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) who have shown a successful response after one year. This update, based on 96-week data from the PULSAR and PHOTON trials, allows for individualized treatment plans, offering the broadest dosing range for an injectable anti-VEGF treatment. Regeneron is also awaiting FDA review for an Eylea HD prefilled syringe.